Oncology research and drug discovery by Cullinan Therapeutics

Cullinan Therapeutics is exploring innovative T cell engager therapies aimed at depleting disease-causing B cells, presenting a new approach to treating autoimmune diseases by addressing their ...

Cullinan Therapeutics is set to host an Immunology Day for investors and analysts on June 10 to present initial clinical data from its CD19- and BCMA-targeted T cell engager therapies for ...

Cullinan Therapeutics released its corporate update alongside its financial results for the first quarter of 2026. The company reported continued momentum and shared details about upcoming ...

Cullinan Therapeutics, in partnership with Taiho Oncology and Taiho Pharmaceutical, announced that the U.S. Food and Drug Administration has accepted its New Drug Application for zipalertinib, ...

Cullinan Therapeutics is preparing to lead industry discussions on the development of clinical trials focused on B cell depleting and immune-resetting therapeutics next week. The company’s Chief ...

Cullinan Therapeutics announced that President and CEO Nadim Ahmed and Chief Medical Officer Jeff Jones will participate in fireside chats at both the TD Cowen 46th Annual Healthcare Conference ...

Cullinan Therapeutics will present significant preclinical data for their CD19-directed bispecific T cell engager, CLN-978. This development is part of their ongoing research efforts in tackling ...

Cullinan Therapeutics is pushing boundaries in healthcare innovation with its focus on autoimmune diseases and cancer treatments. The company is harnessing cutting-edge science to deliver new ...

Cullinan Therapeutics, in collaboration with Taiho Oncology, is making strides in addressing non-small cell lung cancer (NSCLC) by focusing on specific mutations. The company aims to tackle the ...

Cullinan Therapeutics is set to present new data from its Phase 2b REZILIENT2 trial during a mini oral presentation at ESMO 2025 tomorrow. The focus will be on patients with non-small cell lung ...